Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma —backbone or add-on in immune-oncology?

AbstractCyclin-dependent kinases (CDK) control the cell cycle and play a crucial role in oncogenesis. Pharmacologic inhibition of CDK has contributed to the recent clinical approval of dual CDK4/6 inhibitors for the treatment of breast and small cell lung cancer. While the anticancer cell effects of CDK inhibitors are well-established, preclinical and early clinical studies describe additional mechanisms of action such as chemo- and radiosensitization or immune stimulation. The latter offers great potential to incorporate CDK inhibitors in immune-based treatments. However, dosing schedules and accurate timing of each combination partner need to be respected to prevent immune escape and resistance. In this review, we provide a detailed summary of CDK inhibitors in the two solid cancer types head and neck cancer and glioblastoma multiforme; it describes the molecular mechanisms of responsevs. resistance and covers strategies to avoid resistance by the combination of immunotherapy or targeted therapy.
Source: Cancer and Metastasis Reviews - Category: Cancer & Oncology Source Type: research